Uncovering New Therapeutic Targets for Amyotrophic Lateral Sclerosis and Neurological Diseases Using Real‐World Data
Clinical Pharmacology & Therapeutics · 2025-07 · 118 (1) · 242-251
DOI: 10.1002/cpt.3682 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025-05. Verfasst von Mohammadali Alidoost und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of California Los Angeles, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Drug Repositioning, Nervous System Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi iDEA-TECH.
Abstract (Originalsprache)
Although attractive for relevance to real‐world scenarios, real‐world data (RWD) is typically used for drug repurposing and not therapeutic target discovery. Repurposing studies have identified few effective options in neurological diseases such as the rare disease, amyotrophic lateral sclerosis (ALS), which has no disease‐modifying treatments available. We previously reclassified drugs by their simulated effects on proteins downstream of drug targets and observed class‐level effects in the EHR, implicating the downstream protein as the source of the effect. Here, we developed a novel ALS‐focused network medicine model using data from patient samples, the public domain, and consortia. With this model, we simulated drug effects on ALS and measured class effects on overall survival in retrospective EHR studies. We observed an increased but non‐significant risk of death for patients taking drugs with complement system proteins downstream of their targets and experimentally validated drug effects on complement activation. We repeated this for six protein classes, three of which, including multiple chemokine receptors, were associated with a significantly increased risk for death, suggesting that targeting proteins such as CXCR5, CXCR3, chemokine signaling generally, or neuropeptide Y (NPY) could be advantageous therapeutic targets for these patients. We expanded our analysis to the neuroinflammatory condition, myasthenia gravis, and neurodegenerative disease, Parkinson's, and recovered similar effect sizes. We demonstrated the utility of network medicine for testing novel therapeutic effects using RWD and believe this approach may accelerate target discovery in neurological diseases, addressing the critical need for new therapeutic options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, University of California Los Angeles, Los Angeles, California, USA.
- Precision Medicine & Computational Biology, Sanofi Research US, Cambridge, Massachusetts, USA.
- Rare & Neurologic Diseases, Sanofi Research US, Cambridge, Massachusetts, USA.
- Evidence Generation & Decision Sciences, Sanofi Development, Frankfurt, Germany.
- Scientific Relations & Initiatives, Sanofi Research US, Cambridge, Massachusetts, USA.
ORCID-Profile: Mohammadali Alidoost, Mary Clare McCorry, Jennifer L Wilson
Förderung
- Sanofi iDEA-TECH
Zitieren
APA
Alidoost, M., Huang, J. Y., Dermentzaki, G., Blazier, A. S., Gaglia, G., Hammond, T. R., Frau, F., McCorry, M. C., Ofengeim, D., & Wilson, J. L. (2025). Uncovering New Therapeutic Targets for Amyotrophic Lateral Sclerosis and Neurological Diseases Using Real‐World Data. Clinical Pharmacology & Therapeutics, 118(1), 242-251. https://doi.org/10.1002/cpt.3682
Vancouver
Alidoost M, Huang JY, Dermentzaki G, Blazier AS, Gaglia G, Hammond TR, et al. Uncovering New Therapeutic Targets for Amyotrophic Lateral Sclerosis and Neurological Diseases Using Real‐World Data. Clinical Pharmacology & Therapeutics. 2025;118(1):242-251. doi:10.1002/cpt.3682
BibTeX
@article{Alidoost2025,
author = {Alidoost, Mohammadali and Huang, Jeremy Y and Dermentzaki, Georgia and Blazier, Anna S and Gaglia, Giorgio and Hammond, Timothy R and Frau, Francesca and McCorry, Mary Clare and Ofengeim, Dimitry and Wilson, Jennifer L},
title = {Uncovering New Therapeutic Targets for Amyotrophic Lateral Sclerosis and Neurological Diseases Using Real‐World Data},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
volume = {118},
number = {1},
pages = {242--251},
doi = {10.1002/cpt.3682}
}
EUVIMED